|
Vaccine Detail
T. cruzi vaccine using Sendai virus vector expressing amastigote surface protein-2 |
Vaccine Information |
- Vaccine Name: T. cruzi vaccine using Sendai virus vector expressing amastigote surface protein-2
- Target Pathogen: Trypanosoma cruzi
- Target Disease: Chagas disease
- Vaccine Ontology ID: VO_0001394
- Type: Recombinant vector vaccine
- Status: Research
- Host Species as Laboratory Animal Model: mouse
- Antigen: Parasite antigen amastigote surface protein-2 (ASP2) (Duan et al., 2009).
- amastigote surface protein-2
gene engineering:
- Type: Recombinant vector construction
- Description:
- Detailed Gene Information: Click Here.
- Immunization Route: Intranasally
|
Host Response |
Mouse Response
- Host Strain: C57BL/6
- Vaccination Protocol: B6 mice were administrated intranasally with 5 × 10^6 CIU SeV-GFP or SeV-ASP2 (Duan et al., 2009).
- Challenge Protocol: For challenge infections, mice were inoculated with 1000 blood-derived trypomastigotes at the base of the tail 2 weeks after immunization (Duan et al., 2009).
- Efficacy: C57BL/6 mice immunized intranasally with rSeV/dF expressing ASP2 showed significantly suppressed parasitemia and could be protected from lethal T. cruzi challenge (Duan et al., 2009).
|
References |
Duan et al., 2009: Duan X, Yonemitsu Y, Chou B, Yoshida K, Tanaka S, Hasegawa M, Tetsutani K, Ishida H, Himeno K, Hisaeda H. Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2. Vaccine. 2009; 27(44); 6154-6159. [PubMed: 19712768].
|
|